Programs and Projects
Prostate Cancer Clinical Trials - University of Illinois, Chicago (Multicenter Sites)
Agent: soy protein (Genistein)
Contact: Maartin Bosland, DVSC, PhD
DCP Program Director: Howard Parnes, MD
The purpose of this study is to see if a soy protein, genistein, taken daily for up to two years can delay the onset of prostate cancer in men at high risk of recurrence. The study is being conducted under the auspices of the University of Illinois, Chicago. The study is now open to accrual.
[This is a phase 2 randomized double-blind placebo controlled chemoprevention trial of genistein in men at high risk of prostate cancer recurrence. The primary endpoint is the rate of PSA failure as a surrogate for prostate cancer recurrence.]